Brokerages forecast that Trevena, Inc. (NASDAQ:TRVN) will post ($0.27) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Trevena’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.36). Trevena posted earnings of ($0.57) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 52.6%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Trevena will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.45) to ($1.11). For the next year, analysts forecast that the company will post earnings of ($0.76) per share, with EPS estimates ranging from ($0.93) to ($0.56). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Trevena.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35).

Several equities research analysts have weighed in on TRVN shares. Zacks Investment Research cut shares of Trevena from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Barclays PLC cut shares of Trevena from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $15.00 to $2.50 in a research report on Monday, October 16th. Oppenheimer Holdings, Inc. set a $8.00 price target on shares of Trevena and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright dropped their price target on shares of Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Finally, Cowen and Company reissued a “buy” rating and set a $10.00 price target on shares of Trevena in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. Trevena presently has an average rating of “Buy” and an average price target of $9.62.

Trevena (NASDAQ TRVN) opened at 1.76 on Monday. The company’s 50-day moving average is $2.39 and its 200-day moving average is $2.67. Trevena has a 52 week low of $1.57 and a 52 week high of $8.00. The company’s market cap is $105.06 million.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of Trevena by 40.4% in the 1st quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock worth $851,000 after purchasing an additional 66,577 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Trevena by 12.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 6,402 shares during the period. Wells Fargo & Company MN lifted its position in shares of Trevena by 38.4% in the 1st quarter. Wells Fargo & Company MN now owns 222,349 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 61,650 shares during the period. Highbridge Capital Management LLC purchased a new stake in shares of Trevena in the 1st quarter worth about $440,000. Finally, Weiss Multi Strategy Advisers LLC purchased a new stake in shares of Trevena in the 1st quarter worth about $184,000. 60.09% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Trevena, Inc. (TRVN) Will Post Earnings of -$0.27 Per Share” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/23/zacks-analysts-anticipate-trevena-inc-trvn-will-post-earnings-of-0-27-per-share.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.